Psoriasis Clinical Trials in San Francisco
View 22 new treatments for Psoriasis in San Francisco, CA, and nearby areas, such as Antioch, Berkeley, Concord, Daly City, Oakland, Richmond and Vallejo. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
ESK-001 for Psoriasis
Alumis Clinic, Walnut Creek + 1 more
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Verified
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, San Francisco + 1 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 5 - 8 Weeks
Bristol-Myers Squibb
Study Director
Guselkumab for Scalp Psoriasis
Research Clinic, San Francisco + 1 more
This trial studies how Guselkumab, a medication for psoriasis, affects immune cells in patients with moderate to severe scalp psoriasis. Guselkumab works by blocking a protein to reduce inflammation and symptoms.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Raymond Cho, MD, PhD
Principal Investigator
Deucravacitinib for Psoriasis
Research Clinic, San Francisco + 1 more
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Raymond Cho, MD, PhD
Principal Investigator
Goeckerman Therapy for Psoriasis
Research Clinic, San Francisco + 1 more
This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Tina Bhutani, MD
Principal Investigator
Guselkumab for Psoriatic Arthritis
Janssen Clinic, San Leandro + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Tildrakizumab for Psoriasis
Research Clinic, San Francisco + 1 more
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Raymond Cho, MD, PhD
Principal Investigator
Guselkumab for Psoriasis
Research Clinic, San Francisco + 1 more
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Wilson Liao, MD
Principal Investigator
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Stanford + 1 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, San Leandro + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 4 - 6 Weeks
AbbVie Inc.
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions